Clinical Trial Update: A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Pfizer's Phase 3 long-term study of CP-690,550 (tofacitinib) in adults with moderate-to-severe plaque psoriasis and/or psoriatic arthritis has completed, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Tofacitinib (tofacitinib)
• XELJANZ (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2015-08-13